Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Impaired cell surface expression of GLP1R variants determines T2D and obesity risk in humans

Glucagon-like peptide 1 (GLP-1) controls insulin secretion and body weight through activation of its receptor, GLP1R. Large-scale functional analysis of 60 GLP1R genetic variants revealed that loss-of-function (LoF) phenotypes, in particular of cell surface expression, are associated with impaired glucose control and increased adiposity.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Selection process and functional profiling of GLP1R variants.


  1. Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol. Metab. 46, 101102 (2021). A review that discusses the latest GLP1R-based treatments.

    Article  CAS  PubMed  Google Scholar 

  2. El Eid, L., Reynolds, C. A., Tomas, A. & Jones, B. Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics. Pharmacol. Res. 184, 106411 (2022). A review that presents existing GLP1R variants and future therapeutic options.

    Article  CAS  PubMed  Google Scholar 

  3. Bonnefond, A. et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat. Genet. 44, 297–301 (2012). This paper reports a large-scale functional genetics study on rare GPCR variants.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Nogueiras, R., Nauck, M. A. & Tschop, M. H. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat. Metab. 5, 933–944 (2023). A review that presents recent advances in the clinical application of dual and triple GLP1R agonists.

    Article  CAS  PubMed  Google Scholar 

  5. Ulloa-Aguirre, A., Zarinan, T., Gutierrez-Sagal, R. & Tao, Y. X. Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases. Front. Endocrinol. (Lausanne) 13, 934685 (2022). A review that presents the state-of-the-art of pharmacological chaperones for GPCRs.

    Article  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Gao, W. et al. Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity. Nat. Metab. (2023).

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Impaired cell surface expression of GLP1R variants determines T2D and obesity risk in humans. Nat Metab 5, 1654–1655 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing